Mandate

Vinge advises EQT in connection with sale of care giant Aleris

July 02, 2010

EQT III has entered into an agreement to sell the Aleris healthcare group to Investor AB. The transaction value is SEK 4.4 billion with a supplementary purchase price of up to SEK 100 million. The transaction is subject to approval by the relevant competition authorities.

The Vinge team advising EQT consisted of Tuula Tallavaara, David Andersson, Johan Mattsson and Ulrich Ziche. Peter Alstergren provided competition law advice and Carl Gustav De Geer was the responsible partner.

Aleris has approximately 5000 employees and has operations in Sweden, Norway and Denmark. Aleris’ turnover in 2009 was approximately SEK 4 billion.

Related

Vinge advises Greenfood

Vinge advises Greenfood in connection with the divestment of its Fresh Produce business to Dole.
October 21, 2026

Vinge has advised Investor in connection with acquisition of shares in EQT

Vinge has advised Investor in connection with an acquisition of 12,500,000 shares in EQT AB from Wallenberg Investments for a total consideration of approximately SEK 3.5 billion.
October 19, 2026

Vinge has advised Oncopeptides in connection with a directed share issue

Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026